<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344784</url>
  </required_header>
  <id_info>
    <org_study_id>HaEmekMC</org_study_id>
    <secondary_id>0071-14</secondary_id>
    <nct_id>NCT02344784</nct_id>
  </id_info>
  <brief_title>The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder</brief_title>
  <acronym>PPI</acronym>
  <official_title>The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technion, Israel Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that Prepulse inhibition test of acoustic startle
      response is an indicator of objective diagnostic characteristics of attention deficit
      disorder in children and adolescents.

      by demonstrating that Prepulse inhibition test of acoustic startle response is impaired in
      children and adolescents suffering from attention deficit disorder in the relation to the
      normal function described in the literature.

      The investigators will try to prove our hypothesis by an experiment that consists of two
      phases:

      Phase I (about 25 minutes):

      The patient will enter the room, will be asked to sit on a chair, and will be asked to look
      at a computer screen showing silent video of aquarium fish, then the patient will be
      connected to both the Prepulse inhibition test device and the Galvanic skin response device
      and pass the tests.

      Phase II (about 25 minutes):

      After completion of Phase I, each participant will receive his daily regular dose of
      methylphenidate and after an hour and a half from taking the drug, will repeat the tests,
      both the Prepulse inhibition test and the Galvanic skin response test.

      Duration of the entire experiment is 140 minutes (two hours and twenty minutes).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Electromyography (EMG) of the right and the left Orbicularis oculi muscle will be recorded during the Prepulse inhibition test</measure>
    <time_frame>The outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Galvanic skin response will be measured by conductivity (Mv) units during the Prepulse inhibition test</measure>
    <time_frame>The outcome measure will be assessed imediatly during each test and the participants will be followed for the whole duration of the experiment, an expected average of 3 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">46</enrollment>
  <condition>Attention Deficit Disorder</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SR-HLAB EMG</intervention_name>
    <description>Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate</intervention_name>
    <description>The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test</description>
    <other_name>Ritalin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children and adolescents (age 7 to 17.11 years) who are diagnosed with attention deficit
        hyperactivity disorder and are under the Medical surveillance of the mental health clinic
        for children and adolescents at the HaEmek Medical Center- Afula.

        Patients who meet the criteria for inclusion and exclusion will be offered to participate
        in the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between the ages of 7-18

          2. Diagnosed with attention deficit hyperactivity disorder according to Diagnostic and
             statistical manual of mental disorders, fifth edition- Clinical diagnostic interview
             was performed.

          3. Receive drug therapy with methylphenidate doses ranging from 0.3 mg / kg to 1 mg / kg.

          4. The participant is treated with methylphenidate at least two months prior to the
             experiment.

        Exclusion Criteria:

          1. Autism.

          2. Chronic neurological diseases.

          3. Developmental delay.

          4. Psychotic or major effective disorder (psychotic state now or in the past,
             schizophrenia, schizoaffective, depression, bipolar disorder)

          5. Substance abuse.

          6. Mental retardation.

          7. Contraindicated for the treatment of methylphenidate.

          8. Hearing problems.

          9. Pregnancy week 20 and thereafter
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AVRAHAM AVITAL</last_name>
    <role>Study Chair</role>
    <affiliation>Technion, Israel Institute of Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The mental health clinic for children and adolescents at the HaEmek Medical Center</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10. 2008 Jul;(237):1-14.</citation>
    <PMID>18998276</PMID>
  </reference>
  <reference>
    <citation>Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006 Feb;36(2):159-65. Review.</citation>
    <PMID>16420712</PMID>
  </reference>
  <reference>
    <citation>Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics. 2011 Mar;127(3):462-70. doi: 10.1542/peds.2010-0165. Epub 2011 Feb 7.</citation>
    <PMID>21300675</PMID>
  </reference>
  <reference>
    <citation>Biederman J, Quinn D, Weiss M, Markabi S, Weidenman M, Edson K, Karlsson G, Pohlmann H, Wigal S. Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatr Drugs. 2003;5(12):833-41.</citation>
    <PMID>14658924</PMID>
  </reference>
  <reference>
    <citation>Ornitz EM, Hanna GL, de Traversay J. Prestimulation-induced startle modulation in attention-deficit hyperactivity disorder and nocturnal enuresis. Psychophysiology. 1992 Jul;29(4):437-51.</citation>
    <PMID>1410175</PMID>
  </reference>
  <reference>
    <citation>Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry. 1996 Jan 1;39(1):33-41.</citation>
    <PMID>8719124</PMID>
  </reference>
  <reference>
    <citation>Ornitz EM, Russell AT, Hanna GL, Gabikian P, Gehricke JG, Song D, Guthrie D. Prepulse inhibition of startle and the neurobiology of primary nocturnal enuresis. Biol Psychiatry. 1999 Jun 1;45(11):1455-66.</citation>
    <PMID>10356628</PMID>
  </reference>
  <reference>
    <citation>Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul;156(2-3):234-58. Review.</citation>
    <PMID>11549226</PMID>
  </reference>
  <reference>
    <citation>Hawk LW Jr, Yartz AR, Pelham WE Jr, Lock TM. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder. Psychopharmacology (Berl). 2003 Jan;165(2):118-27. Epub 2002 Nov 1.</citation>
    <PMID>12417963</PMID>
  </reference>
  <reference>
    <citation>Feifel D, Minassian A, Perry W. Prepulse inhibition of startle in adults with ADHD. J Psychiatr Res. 2009 Jan;43(4):484-9. doi: 10.1016/j.jpsychires.2008.06.004. Epub 2008 Jul 31.</citation>
    <PMID>18674783</PMID>
  </reference>
  <reference>
    <citation>Hanlon MC, Karayanidis F, Schall U. Intact sensorimotor gating in adult attention deficit hyperactivity disorder. Int J Neuropsychopharmacol. 2009 Jun;12(5):701-7. doi: 10.1017/S1461145708009711. Epub 2008 Dec 2.</citation>
    <PMID>19046483</PMID>
  </reference>
  <reference>
    <citation>Ashare RL, Hawk LW Jr, Shiels K, Rhodes JD, Pelham WE Jr, Waxmonsky JG. Methylphenidate enhances prepulse inhibition during processing of task-relevant stimuli in attention-deficit/hyperactivity disorder. Psychophysiology. 2010 Sep;47(5):838-45. doi: 10.1111/j.1469-8986.2010.01001.x. Epub 2010 Mar 10.</citation>
    <PMID>20233343</PMID>
  </reference>
  <reference>
    <citation>Takahashi H, Hashimoto R, Iwase M, Ishii R, Kamio Y, Takeda M. Prepulse inhibition of startle response: recent advances in human studies of psychiatric disease. Clin Psychopharmacol Neurosci. 2011 Dec;9(3):102-10. doi: 10.9758/cpn.2011.9.3.102. Epub 2011 Dec 31.</citation>
    <PMID>23429840</PMID>
  </reference>
  <reference>
    <citation>Sable JJ, Kyle MR, Knopf KL, Schully LT, Brooks MM, Parry KH, Diamond RE, Flink LA, Stowe R, Suna E, Thompson IA. The Sensory Gating Inventory as a potential diagnostic tool for attention-deficit hyperactivity disorder. Atten Defic Hyperact Disord. 2012 Sep;4(3):141-4. doi: 10.1007/s12402-012-0079-1. Epub 2012 May 27.</citation>
    <PMID>22644992</PMID>
  </reference>
  <reference>
    <citation>Schulz-Juergensen S, Thiemann A, Gebhardt J, Baumgarten-Walczak A, Eggert P. Prepulse inhibition of acoustic startle and the influence of methylphenidate in children with ADHD. J Atten Disord. 2014 Feb;18(2):117-22. doi: 10.1177/1087054712448960. Epub 2012 Jun 19.</citation>
    <PMID>22713361</PMID>
  </reference>
  <reference>
    <citation>Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D. Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res. 2013 Jan 30;205(1-2):117-26. doi: 10.1016/j.psychres.2012.08.013. Epub 2012 Sep 25.</citation>
    <PMID>23017654</PMID>
  </reference>
  <reference>
    <citation>Kohl S, Heekeren K, Klosterkötter J, Kuhn J. Prepulse inhibition in psychiatric disorders--apart from schizophrenia. J Psychiatr Res. 2013 Apr;47(4):445-52. doi: 10.1016/j.jpsychires.2012.11.018. Epub 2013 Jan 1. Review.</citation>
    <PMID>23287742</PMID>
  </reference>
  <reference>
    <citation>Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med. 2014 Feb 27;370(9):838-46. doi: 10.1056/NEJMcp1307215. Review. Erratum in: N Engl J Med. 2015 Jan 8;372(2):197. Dosage error in text.</citation>
    <PMID>24571756</PMID>
  </reference>
  <reference>
    <citation>Gebhardt J, Schulz-Juergensen S, Eggert P. Maturation of prepulse inhibition (PPI) in childhood. Psychophysiology. 2012 Apr;49(4):484-8. doi: 10.1111/j.1469-8986.2011.01323.x. Epub 2011 Dec 16.</citation>
    <PMID>22176532</PMID>
  </reference>
  <reference>
    <citation>Swerdlow NR, Braff DL, Geyer MA. Cross-species studies of sensorimotor gating of the startle reflex. Ann N Y Acad Sci. 1999 Jun 29;877:202-16. Review.</citation>
    <PMID>10415651</PMID>
  </reference>
  <reference>
    <citation>Grim PF. A sustained attention comparison of children and adults using reaction time set and the GSR. J Exp Child Psychol. 1967 Mar;5(1):26-38.</citation>
    <PMID>6038515</PMID>
  </reference>
  <reference>
    <citation>Okkesim Ş, Kara S, Kaya MG, Asyali MH. Analysis of coronary angiography related psychophysiological responses. Biomed Eng Online. 2011 Aug 11;10:71. doi: 10.1186/1475-925X-10-71.</citation>
    <PMID>21834993</PMID>
  </reference>
  <reference>
    <citation>Kumari V, Fannon D, Geyer MA, Premkumar P, Antonova E, Simmons A, Kuipers E. Cortical grey matter volume and sensorimotor gating in schizophrenia. Cortex. 2008 Oct;44(9):1206-14. doi: 10.1016/j.cortex.2007.11.007. Epub 2008 Jan 20.</citation>
    <PMID>18761134</PMID>
  </reference>
  <reference>
    <citation>Molina V, Montes C, Tamayo P, Villa R, Osuna MI, Pérez J, Sancho C, López-Albuquerque T, Cardoso A, Castellano O, López DE. Correlation between prepulse inhibition and cortical perfusion during an attentional test in schizophrenia. A pilot study. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):53-61. doi: 10.1016/j.pnpbp.2008.10.011. Epub 2008 Oct 30.</citation>
    <PMID>19000732</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>HaEmek Medical Center, Israel</investigator_affiliation>
    <investigator_full_name>ESSAM DAOD</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>ADD</keyword>
  <keyword>ADHD</keyword>
  <keyword>PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

